ICV Delegation Visit Greater China 2017 will provide insights into operating throughout China and U.S. – China relations, as well as the opportunity to explore potential investment and cross-border partnering opportunities.
Within healthcare, the Chinese market is developing rapidly, with technological breakthroughs that are driving innovation and an aggressive move towards cross-border collaboration, both for investments and licensing.
One-on-one meetings will be carefully curated based upon targeted objectives and designed to facilitate a variety of different partnering mechanisms for co-development and/or investment.
Because investors are less transaction oriented in China than in other markets, ICV will provide sustained follow-ups and help companies to establish long-term relationships after the ICV Delegation Visit Greater China 2017.
Delegates will also have the opportunity to participate in the 4th BioCentury China Healthcare Summit, which will gather top thinkers from industry, academia and finance to identify who will lead China’s biopharma innovation ecosystem, how innovation will be funded, and the business strategies required to transform both domestic and multinational biopharmas and medtech companies as China advances its innovation agenda. Attendance is limited at this strategic, VIP-only event to ensure intimate dialogue and networking among peers.
With a targeted approach and sustained engagement, entry into Greater China can be transformational.
Japan is one of the world’s most developed and sophisticated healthcare markets, especially in the biopharmaceutical and medical technology space. Behind the U.S., Japan is the second world’s second-largest pharmaceutical market. Japan not only has a complex and rewarding reimbursement scheme for marketed products, but a vibrant R&D landscape with particularly innovative incentives. In areas such as Regenerative Medicine, for instance, Japan is the global leader, having implemented a unique regulatory mechanism in 2014 for the expedited approval of Regenerative Medicines.
On a macro level, the country’s rapidly aging population, with the 65-and-older demographic on track to increase from 25% to 40% of the population, presents huge challenges for government and the economy and creates huge opportunities for innovation and international expansion. Because of this, Japan is increasingly opening up to foreign markets and to international companies operating within the country.
Taiwan’s boom in biotechnology means licensing, partnering and investment agreements are at an all-time high.
ICV will host Delegation Visit Taiwan, a week-long roadshow with one-on-one meetings with investors and access to BioTaiwan 2017.
Unique characteristics make the biotech industry in Taiwan an appealing prospect to the global life science community looking for partnership, investment or licensing opportunities.
Delegation Visit China and Singapore, Spring 2017
This spring, ICV introduced one of its innovative biopharmaceuticals clients to potential partners and investors in China and Singapore.
With nearly three dozen one-on-one meetings scheduled in total, adding up to tens of billions in combined fund AUM, interest in Asia has proved strong for U.S. biopharmaceuticals. These meetings have had direct follow-up implications, with several investors now conducting a deeper dive.
Chinese partners and investors are continuing to look for mid to late-stage clinical assets combatting a variety of severe diseases in China.
In Singapore, interest is in early-stage opportunities, with more of a focus on platform technologies, medical devices and hospital-oriented services.
Delegation Visit Greater China: Beijing, Shanghai and Hong Kong, Winter 2017